Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial

Kenneth G. Saag*, Nicola Pannacciulli, Piet Geusens, Jonathan D. Adachi, Osvaldo D. Messina, Jorge Morales-Torres, Ronald Emkey, Peter W. Butler, Xiang Yin, Willem F. Lems

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1174-1184
Number of pages11
JournalArthritis & Rheumatology
Volume71
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • CORTICOSTEROID-INDUCED OSTEOPOROSIS
  • BONE-MINERAL DENSITY
  • POSTMENOPAUSAL WOMEN
  • ZOLEDRONIC ACID
  • VERTEBRAL FRACTURE
  • PREVENTION
  • ALENDRONATE
  • MULTICENTER
  • EXTENSION
  • THERAPY

Cite this